New York State Common Retirement Fund Has $25.45 Million Position in Cryoport, Inc. (NASDAQ:CYRX)

New York State Common Retirement Fund boosted its position in Cryoport, Inc. (NASDAQ:CYRX - Free Report) by 29.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,642,752 shares of the company's stock after acquiring an additional 378,340 shares during the quarter. New York State Common Retirement Fund owned 3.36% of Cryoport worth $25,446,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its position in Cryoport by 2.1% in the third quarter. Vanguard Group Inc. now owns 3,559,092 shares of the company's stock valued at $48,795,000 after purchasing an additional 74,037 shares during the period. Cadian Capital Management LP raised its position in Cryoport by 298.2% in the third quarter. Cadian Capital Management LP now owns 2,656,739 shares of the company's stock valued at $36,424,000 after purchasing an additional 1,989,598 shares during the period. Invesco Ltd. raised its position in Cryoport by 17.9% in the third quarter. Invesco Ltd. now owns 2,062,481 shares of the company's stock valued at $28,277,000 after purchasing an additional 313,853 shares during the period. Assenagon Asset Management S.A. raised its position in Cryoport by 487.7% in the fourth quarter. Assenagon Asset Management S.A. now owns 1,393,156 shares of the company's stock valued at $21,580,000 after purchasing an additional 1,156,106 shares during the period. Finally, Massachusetts Financial Services Co. MA raised its position in Cryoport by 28.3% in the third quarter. Massachusetts Financial Services Co. MA now owns 1,356,500 shares of the company's stock valued at $18,598,000 after purchasing an additional 298,995 shares during the period. 92.90% of the stock is owned by hedge funds and other institutional investors.

Cryoport Stock Up 2.2 %

NASDAQ:CYRX traded up $0.35 during mid-day trading on Friday, reaching $16.38. The stock had a trading volume of 217,146 shares, compared to its average volume of 377,026. The company has a market capitalization of $805.24 million, a price-to-earnings ratio of -7.45 and a beta of 1.60. Cryoport, Inc. has a 1-year low of $9.00 and a 1-year high of $24.17. The stock's 50 day simple moving average is $16.87 and its two-hundred day simple moving average is $14.96. The company has a debt-to-equity ratio of 0.82, a current ratio of 11.73 and a quick ratio of 11.16.

Cryoport (NASDAQ:CYRX - Get Free Report) last posted its quarterly earnings results on Tuesday, March 12th. The company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.19). The firm had revenue of $57.26 million during the quarter, compared to analyst estimates of $58.27 million. Cryoport had a negative return on equity of 11.86% and a negative net margin of 42.69%. Equities analysts anticipate that Cryoport, Inc. will post -1.31 EPS for the current year.

Insider Buying and Selling

In other Cryoport news, CEO Jerrell Shelton sold 2,631 shares of Cryoport stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $17.54, for a total value of $46,147.74. Following the completion of the transaction, the chief executive officer now directly owns 692,182 shares in the company, valued at $12,140,872.28. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Cryoport news, Director Ramkumar Mandalam sold 3,217 shares of Cryoport stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $14.68, for a total value of $47,225.56. Following the completion of the transaction, the director now directly owns 43,187 shares in the company, valued at $633,985.16. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Jerrell Shelton sold 2,631 shares of Cryoport stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $17.54, for a total value of $46,147.74. Following the completion of the transaction, the chief executive officer now owns 692,182 shares of the company's stock, valued at $12,140,872.28. The disclosure for this sale can be found here. Over the last three months, insiders sold 73,940 shares of company stock worth $1,147,538. Corporate insiders own 10.10% of the company's stock.

Analysts Set New Price Targets

Several research analysts have commented on CYRX shares. UBS Group raised their price objective on Cryoport from $14.50 to $17.00 and gave the company a "neutral" rating in a research report on Friday, March 15th. Needham & Company LLC dropped their target price on Cryoport from $19.00 to $18.00 and set a "buy" rating on the stock in a research report on Wednesday, March 13th. Stephens reaffirmed an "equal weight" rating and set a $17.00 target price on shares of Cryoport in a research report on Wednesday, March 13th. Finally, Jefferies Financial Group assumed coverage on Cryoport in a research report on Thursday, April 4th. They set a "buy" rating and a $21.00 target price on the stock. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to MarketBeat.com, Cryoport currently has a consensus rating of "Hold" and a consensus price target of $18.63.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.